rs28942074
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The NM_000053.4(ATP7B):c.2333G>T(p.Arg778Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000044 in 1,614,178 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R778Q) has been classified as Pathogenic.
Frequency
Consequence
NM_000053.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATP7B | NM_000053.4 | c.2333G>T | p.Arg778Leu | missense_variant | 8/21 | ENST00000242839.10 | NP_000044.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATP7B | ENST00000242839.10 | c.2333G>T | p.Arg778Leu | missense_variant | 8/21 | 1 | NM_000053.4 | ENSP00000242839 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152178Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000136 AC: 34AN: 249404Hom.: 0 AF XY: 0.000126 AC XY: 17AN XY: 135330
GnomAD4 exome AF: 0.0000431 AC: 63AN: 1461882Hom.: 0 Cov.: 31 AF XY: 0.0000426 AC XY: 31AN XY: 727242
GnomAD4 genome AF: 0.0000525 AC: 8AN: 152296Hom.: 0 Cov.: 32 AF XY: 0.0000672 AC XY: 5AN XY: 74452
ClinVar
Submissions by phenotype
Wilson disease Pathogenic:14Other:2
Pathogenic, no assertion criteria provided | curation | SingHealth Duke-NUS Institute of Precision Medicine | Jun 07, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 29, 2020 | The p.Arg778Leu variant in ATP7B is the most common pathogenic variant causative for Wilson disease in Asian populations, with many homozygous and compound heterozygous probands reported and at least 4 segregations in affected relatives from 4 families (Hua 2016, Shimizu 1999, Shiono 2001, Wu 2001, Yoo 2002). It has also been reported in by clinical laboratories in ClinVar (Variation ID 3852) and has been identified in 0.189% (37/19538) of East Asian chromosomes by gnomAD (http://gnomad.broadinstitute.org). This frequency is consistent with a recessive carrier frequency. In vitro functional studies have shown that this variant results in mislocalization of the protein and abnormal copper transport (Forbes 1998, van den Berghe 2009, Zhu 2015). Computational prediction tools and conservation analyses suggest an impact to the protein. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Wilson disease. ACMG/AMP criteria applied: PM3_VeryStrong, PP1_Strong, PS3_Supporting, PP3. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | May 02, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 778 of the ATP7B protein (p.Arg778Leu). This variant is present in population databases (rs28942074, gnomAD 0.2%). This missense change has been observed in individual(s) with Wilson disease (PMID: 10453196, 11405812, 25086856, 25988284, 27398169, 28212618). ClinVar contains an entry for this variant (Variation ID: 3852). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATP7B protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects ATP7B function (PMID: 9837819, 10942420, 19937698). This variant disrupts the p.Arg778 amino acid residue in ATP7B. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11243728, 11479773, 16998622, 17160357, 23518715). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 19, 2019 | NM_000053.3(ATP7B):c.2333G>T(R778L) is classified as pathogenic in the context of Wilson disease. Sources cited for classification include the following: PMID 17587212 and 11405812. Classification of NM_000053.3(ATP7B):c.2333G>T(R778L) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 02, 2022 | The ATP7B c.2333G>T; p.Arg778Leu variant (rs28942074) is a common pathogenic variant in Asian populations found homozygous and compound heterozygous in several individuals affected with Wilson disease (Li 2013, Wu 2001, Xiao 2019). Functional analyses of the variant protein show reduced expression, defective copper excretion, and subcellular mislocalization (van den Berghe 2009, Zhu 2015). This variant is reported in ClinVar (Variation ID: 3852) and is found in East Asian population with an allele frequency of 0.2% (37/19538 alleles) in the Genome Aggregation Database. The arginine at codon 778 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.947). Based on available information, this variant is considered to be pathogenic. References: Li K et al. Mutational analysis of ATP7B in north Chinese patients with Wilson disease. J Hum Genet. 2013 Feb;58(2):67-72. PMID: 23235335. van den Berghe PV et al. Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin. Hepatology. 2009 Dec;50(6):1783-95. PMID: 19937698. Wu ZY et al. Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in chinese patients with Wilson disease. Arch Neurol. 2001 Jun;58(6):971-6. PMID: 11405812. Xiao H et al. Mutation Analysis of the ATP7B Gene in Seven Chinese Families with Wilson's Disease. Digestion. 2019;99(4):319-326. PMID: 30384382. Zhu M et al. Defective roles of ATP7B missense mutations in cellular copper tolerance and copper excretion. Mol Cell Neurosci. 2015 Jul;67:31-6. PMID: 26032686. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 14, 2017 | Variant summary: The ATP7B c.2333G>T (p.Arg778Leu) variant involves the alteration of a conserved nucleotide, resulting in a missense change that lies within the P-type ATPase, transmembrane domain (InterPro). 5/5 in silico tools predict a damaging outcome for this variant. This variant was found in 8/246194 control chromosomes at a frequency of 0.0000325, which does not exceed the estimated maximal expected allele frequency of a pathogenic ATP7B variant (0.0054006). This variant has been identified in numerous patients as compound heterozygous and homozygous, and multiple other mutations have been reported in patients at the same codon (R778L, R778G, R778Q, and R778W), suggesting the site is a mutational hotspot. Functional studies in yeast showed that copper transport was severely impaired and the variant protein was mislocalized to the ER and/or lysosomes (Forbes_2000). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2011 | - - |
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | The ATP7B c.2333G>T (p.Arg778Leu) variant is widely reported in the literature as a common variant in Wilson disease (WD) in Asian populations. Across a selection of available literature, the p.Arg778Leu variant has been identified in 114 WD patients of Chinese, Japanese, and Korean ancestry, including 32 homozygotes, 57 compound heterozygotes, and 32 heterozygotes. The variant was also found in a heterozygous state in six unaffected parents of probands (Thomas et al. 1995; Kusuda et al. 2000; Wu et al. 2001; Yoo et al. 2002; Bae et al. 2009; Hua et al. 2016, Zong et al. 2016). Wu et al. (2001) found that patients who were homozygous for the p.Arg778Leu variant had an earlier age of onset (14.2 years vs. 22.0 years) and neurologic rather than hepatic symptoms at onset when compared to compound heterozygotes. The p.Arg778Leu variant was absent from 60 controls (Wu et al. 2001), but is reported at a frequency of 0.00232 in the East Asian population of the Exome Aggregation Consortium. Van den Berghe et al. (2009) demonstrated reduced protein expression and mislocalization to the endoplasmic reticulum of the p.Arg778Leu variant protein compared to wild type. Zhu et al. (2015) showed that the p.Arg778Leu variant caused reduced copper excretion and impaired the protective effect of the wild type protein on cell exposed to excess copper. Based on the collective evidence, the p.Arg778Leu variant is classified as pathogenic for Wilson disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Provincial Medical Genetics Program of British Columbia, University of British Columbia | Jan 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 21, 2024 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 31, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Beijing Key Laboratry for Genetics of Birth Defects, Beijing Children's Hospital | Feb 28, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Mar 07, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 21, 2022 | Functional expression studies with the R778L variant in yeast showed defective rescue of normal copper transport function (Forbes et al., 1998). Expression studies in CHO cells demonstrated this variant disrupted both the normal localization and trafficking of ATP7B (Zhu et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24253677, 24878384, 26782526, 27398169, 30366773, 16998622, 11479773, 23518715, 19419418, 34458581, 34666712, 29979436, 35357466, 9837819, 11405812, 19937698, 10942420, 23235335, 10721669, 25086856, 19783880, 22692182, 7626145, 26032686, 14986826, 21796144, 23843956, 25988284, 12812649, 28212618, 29907136, 17587212, 11243728, 17160357, 10453196, 9554743, 16133174, 29961769, 30655162, 31010795, 29181760, 30384382, 30558096, 31474638, 31637888, 31783295, 31804371, 31743419, 30275481, 32005694, 34539730, 34240825, 34345444, 33096383, 34324271, 33668890, 32911910, 33763395, 32794656) - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 20, 2021 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 23, 2014 | The p.R778L pathogenic mutation (also known as c.2333G>T), located in coding exon 8 of the ATP7B gene, results from a G to T substitution at nucleotide position 2333. The arginine at codon 778 is replaced by leucine, an amino acid with dissimilar properties.This pathogenic alteration has been observed in both the homozygous and compound heterozygous state in patients with a biochemical diagnosis of Wilson disease (Thomas GR, et al. Nat. Genet. 1995;9(2):210-7). Functional studies have determined that this mutation disrupts normal localization of the ATP7B protein, has reduced copper transport ability, and causes the affected protein to fail to localize into the Golgi apparatus, possibly due to misfolding (Forbes JR, et al. Hum. Mol. Genet. 2000;9(13):1927-35 and van den Berghe PV, et al. Hepatology 2009;50(6):1783-95). In addition, population studies have found this alteration to be a founder mutation in several Asian populations (Gu S, et al. PLoS ONE 2013;8(7):e66526 and Hui J, et al. World J Pediatr 2013;9(4):361-4). Based on the supporting evidence, p.R778L is interpreted as a disease-causing mutation. - |
ATP7B-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 06, 2023 | The ATP7B c.2333G>T variant is predicted to result in the amino acid substitution p.Arg778Leu. This variant has been reported to be causative for Wilson disease both in the homozygous state and in the compound heterozygous state with a second pathogenic variant (see for example Thomas et al. 1995. PubMed ID: 7626145; Chuang et al. 1996. PubMed ID: 8782057; Hua et al. 2016. PubMed ID: 27398169). This variant is reported to be a common pathogenic variant in Asian populations (Thomas et al. 1995. PubMed ID: 7626145; Weiss et al. 2016. PubMed ID: 20301685). Alternate nucleotide changes affecting the same amino acid (p.Arg778Gln, p.Arg778Gly, p.Arg778Trp) have been reported in individuals with Wilson disease (Figus et al. 1995. PubMed ID: 8533760; Chuang et al. 1996. PubMed ID: 8782057; Shah et al. 1997. PubMed ID: 9311736). This variant has been reported 37 times among ~281,000 alleles (~0.01%) in a large population database, but is enriched in the East Asian population (https://gnomad.broadinstitute.org/variant/13-52532469-C-A). In ClinVar, this variant in interpreted as pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/3852/). Taken together, we interpret this variant as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at